Citigroup Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang maintains a Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and raises the price target from $40 to $45.
July 02, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst David Hoang maintains a Buy rating on Longboard Pharmaceuticals and raises the price target from $40 to $45.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100